Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

AstraZeneca sales decline slows as it waits for medicine to work

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 12:48pm CEST
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

LONDON (Reuters) - AstraZeneca's (>> AstraZeneca) drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes.

LONDON (Reuters) - AstraZeneca's (>> AstraZeneca) drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes.

Product sales were down 3 percent compared with an 11 percent fall during the first half of the year. Emerging markets proved a bright spot, with Chinese sales up 12 percent, the company said on Thursday.

Chief Executive Pascal Soriot believes the drugmaker has reached a turning-point as its pipeline of new medicines starts to deliver and the impact of patent losses recedes. Consensus forecasts also point to a recovery in sales and profits from next year.

Still, the speed of AstraZeneca's turnaround remains uncertain as the No.2 British drugmaker goes head to head with industry giants like Roche (>> Roche Holding Ltd.), Bristol-Myers Squibb (>> Bristol-Myers Squibb Company) and Merck & Co (>> Merck and Company) in the fast-growing but fiercely competitive cancer drug market.

Total revenue rose 9 percent to $6.23 billion (£4.7 billion) in the quarter, helped by a $997 million payment from Merck, which struck a cancer drug partnership deal with the British group in July. Sales of Crestor, while down 16 percent, were also higher than expected.

That was not enough to stop a fall in core earnings per share (EPS), which exclude some items, of 15 percent to $1.12. But the overall results were better than expected and the shares had risen around 1 percent by 1130 GMT.

Industry analysts, on average, had forecast quarterly earnings of $1.04 and revenue of $5.95 billion, according to Thomson Reuters data.

For the full year, AstraZeneca said it expected 2017 core EPS to be "towards the favourable end of the guidance range of a low to mid teens percentage decline".

Soriot said he remained confident AstraZeneca could achieve annual revenue of more than $40 billion in 2023, despite scepticism among analysts like Trinity Delta's Mick Cooper who said it was "difficult" to see how this would be done.

Soriot first gave a bullish long-term forecast of 2023 revenue hitting $45 billion back in 2014, as he fended off a takeover attempt by Pfizer (>> Pfizer). Since then, a stronger dollar has shifted the target slightly but Soriot said the expectation in constant exchange rates had not changed.

"Our long-range plan so far reconfirms that we can get to the $40-41 billion dollars at today's currency rates that we communicated back in 2014," he said.


Results from drug trials remain critical.

AstraZeneca suffered the biggest ever daily fall in its shares three months ago, following the initial failure of a key lung cancer trial dubbed Mystic.

But it has since rebuilt investor expectations, helped by impressive data from two other lung cancer trials, involving the drugs Tagrisso and Imfinzi, that were presented at a medical congress in Madrid in September.

And just last week it won early U.S. approval for Calquence, marking its first entry into the blood cancer market.

However, results from another immunotherapy lung cancer trial called Arctic have been delayed again and are now not expected until the first half of 2018.

AstraZeneca is also refilling its drug pipeline in other areas, such as respiratory medicine. A new drug for severe asthma is awaiting U.S. approval by the end of this year and could get an approval recommendation in Europe as early as Friday.

(Reporting by Ben Hirschler; Editing by Keith Weir and Mark Potter)

By Ben Hirschler

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.14% 53.675 Delayed Quote.-12.47%
MERCK AND COMPANY -0.47% 60.995 Delayed Quote.8.90%
PFIZER -0.66% 36.225 Delayed Quote.0.00%
ROCHE HOLDING LTD. -0.44% 215.5 Delayed Quote.-12.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
01:32pInitiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug..
12:44pASTRAZENECA : With an AstraZeneca cancer drug in one hand, $37M in the other, Sh..
06/20ASTRAZENECA : Scotland to house world-first manufacturing innovation centre
06/19FASTER MEDICINE : 56 million innovation centre for Scotland
06/19ASTRAZENECA : to Share Latest Data from an Industry-Leading Portfolio That Aims ..
06/19ASTRAZENECA : Medicines manufacturing centre planned to strengthen UK pharma
06/19ASTRAZENECA : to share latest data from an industry-leading portfolio that aims ..
06/18FASTER MEDICINE : £56 million innovation centre for Scotland
06/16ASTRAZENECA : £56m medicine base is set for Inchinnan
06/152.5B U.K. fund, Alzheimer`s failure, Alexion-Complement, Targovax tumbles and..
More news
News from SeekingAlpha
06/19ALZHEIMER'S DISEASE : A History Of Drug Failures 
06/19Allena Pharma to file IND for ALLN-346 in H1 2019 
06/15Avoiding The 'Black Hole' Of Disease Development 
06/153 THINGS IN BIOTECH, JUNE 14 : Another Big Win In A Rare Area For Merck 
06/14YOUR DAILY PHARMA SCOOP : Sage On Accelerated Path, GenSight Positive Data, Astr.. 
Financials ($)
Sales 2018 22 361 M
EBIT 2018 5 330 M
Net income 2018 1 982 M
Debt 2018 14 629 M
Yield 2018 3,88%
P/E ratio 2018 37,38
P/E ratio 2019 30,22
EV / Sales 2018 4,66x
EV / Sales 2019 4,39x
Capitalization 89 519 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 74,5 $
Spread / Average Target 5,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA5.04%89 519
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625